Jones, J. A., Ruppert, A. S., Zhao, W., Lin, T. S., Rai, K., Peterson, B., . . . Byrd, J. C. (2013). Chronic lymphocytic leukemia patients with high-risk genomic features have inferior outcome on successive CALGB trials with alemtuzumab consolidation: Subgroup analysis from CALGB 19901 and CALGB 10101.
Style de citation ChicagoJones, Jeffrey A., et al. Chronic Lymphocytic Leukemia Patients With High-risk Genomic Features Have Inferior Outcome On Successive CALGB Trials With Alemtuzumab Consolidation: Subgroup Analysis From CALGB 19901 and CALGB 10101. 2013.
Style de citation MLAJones, Jeffrey A., et al. Chronic Lymphocytic Leukemia Patients With High-risk Genomic Features Have Inferior Outcome On Successive CALGB Trials With Alemtuzumab Consolidation: Subgroup Analysis From CALGB 19901 and CALGB 10101. 2013.